Akebia Therapeutics, Inc. (AKBA)

0.3375 -0.0085 (-2.46%) As of 10:52AM EDT. Market open.

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098
https://www.akebia.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 426

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John P. Butler MBA	CEO, Pres & Director	1.36M	N/A	1964
Mr. David A. Spellman	Sr. VP, CFO & Treasurer	790.54k	N/A	1977
Mr. Michel Dahan	Sr. VP & COO	795.39k	N/A	1979
Mr. Dell Faulkingham	Sr. VP & Chief Commercial Officer	797.88k	N/A	1973
Dr. Steven Keith Burke	Sr. VP of R&D and Chief Medical Officer	821.54k	N/A	1961
Ms. Violetta Cotreau	Sr. VP, Chief Accounting Officer & Principal Accounting Officer	N/A	N/A	1973
Ms. Nicole R. Hadas	Sr. VP, Chief Legal Officer & Sec.	N/A	N/A	1973
Mercedes Carrasco	Director of Corp. Communications	N/A	N/A	N/A
Mr. Douglas Jermasek M.B.A.	VP of Marketing & Strategy	N/A	N/A	N/A
Ms. Tamara Dillon	Sr. VP of HR & Chief People Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Akebia Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.